March 9, 2021

OICR-affiliated researchers awarded $6.6 million in funding from CIHR

From top-left: Drs. Courtney Jones, Faiyaz Notta, Rima Al-Awar, Trevor Pugh, Naoto Hirano, Hartland Jackson and Kieran Campbell.

The funding will support projects ranging from drug discovery to cancer stem cells

Seven OICR-affiliated researchers have been awarded $6.6 million in funding from the Canadian Institutes for Health Research (CIHR) through its Project Grants program, which is designed to capture ideas with the greatest potential to advance health and research. The funded projects will help support key OICR research in drug discovery, pancreatic cancer, immunotherapy, genomics and circulating tumour DNA, and cancer stem cells.

Dr. Rima Al-Awar
Head, Therapeutic Innovation and Drug Discovery, OICR
The Discovery and Optimization of NUAK Inhibitors: A Novel Approach to Target Hippo Pathway Driven Cancers

Dr. Kieran Campbell
OICR Affiliate, Scientist & Principal Investigator, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital
Characterizing immune evasion in pancreatic adenocarcinoma: an integrative computational and experimental approach to understanding aberrant antigen presentation

Dr. Naoto Hirano
OICR Clinician Scientist, Senior Scientist, Princess Margaret Cancer Centre
Development of TCR-engineered T cells against novel NY-ESO-1 epitopes for the treatment of triple negative breast cancer

Dr. Hartland Jackson
OICR Investigator, Investigator, Lunenfeld-Tanenbaum Research Institute, Sinai Health
Targeting chemotherapy resistant multi-cellular environments in pancreatic cancer

Dr. Courtney Jones
OICR Investigator, Senior Scientist, Princess Margaret Cancer Centre
Characterization and Targeting of SIRT3 in Acute Myeloid Leukemia Stem Cells

Dr. Faiyaz Notta
OICR Associate, Co-Lead, OICR PanCuRx Translational Research Initiative, Scientist, Princess Margaret Cancer Centre
Impact of copy number imbalances in mutant KRAS on pancreatic cancer chemoresistance and metastases

Dr. Trevor Pugh
Senior Investigator and Director, Genomics, OICR
Understanding inevitable relapse of multiple myeloma following highly-effective anti-BCMA treatment